{
    "2021-12-06": [
        [
            {
                "time": "",
                "original_text": "加购OK镜后：昊海生科被质疑未走上医美赛道？",
                "features": {
                    "keywords": [
                        "昊海生科",
                        "OK镜",
                        "医美",
                        "质疑"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：医保谈判落地 释放积极信号",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医保谈判",
                        "积极信号"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}